Skip to main content

ADVERTISEMENT

Yvette C. Terrie, BS Pharm, RPh

Conference Coverage
01/31/2023
At the 64th ASH Annual Meeting, researchers provided information about the multinational, multicenter, randomized, controlled Phase III PACIFICA trial, which aims to gather data to validate the efficacy and safety of pacritinib vs the...
At the 64th ASH Annual Meeting, researchers provided information about the multinational, multicenter, randomized, controlled Phase III PACIFICA trial, which aims to gather data to validate the efficacy and safety of pacritinib vs the...
At the 64th ASH Annual Meeting,...
01/31/2023
Journal of Clinical Pathways
Commentary
01/13/2022
In honor of National Pharmacist Day, Yvette C Terrie reflects on her journey as a pharmacist and the importance of the profession.
In honor of National Pharmacist Day, Yvette C Terrie reflects on her journey as a pharmacist and the importance of the profession.
In honor of National Pharmacist...
01/13/2022
Pharmacy Learning Network
News
09/12/2022
General physicians and other providers are progressively referring patients requiring cerumen disimpaction to otolaryngologist physicians and permitting advanced practice providers to perform these procedures, suggesting a shift in landscape...
General physicians and other providers are progressively referring patients requiring cerumen disimpaction to otolaryngologist physicians and permitting advanced practice providers to perform these procedures, suggesting a shift in landscape...
General physicians and other...
09/12/2022
Journal of Clinical Pathways
News
02/27/2023
According to a study published in The Journal of the American Dental Association, researchers found considerable geographic and insurance status disparities with respect to accessing oral health care among pediatric patients in different...
According to a study published in The Journal of the American Dental Association, researchers found considerable geographic and insurance status disparities with respect to accessing oral health care among pediatric patients in different...
According to a study published...
02/27/2023
Dentistry
Commentary
11/10/2023
In a news story released in October 2023, CVS Health announced that its company was voluntarily removing some of the most purchased OTC cold and cough medications from its stores.
In a news story released in October 2023, CVS Health announced that its company was voluntarily removing some of the most purchased OTC cold and cough medications from its stores.
In a news story released in...
11/10/2023
Pharmacy Learning Network
Bottle with pills pouring out
Commentary
01/25/2023
In her latest commentary, Yvette Terrie considers how pharmacists can work in collaboration with patients and other providers to treat opioid use disorder.
In her latest commentary, Yvette Terrie considers how pharmacists can work in collaboration with patients and other providers to treat opioid use disorder.
In her latest commentary, Yvette...
01/25/2023
Pharmacy Learning Network
News
06/20/2022
After failure of type 1b MET tyrosine kinase inhibitors, foretinib shows potent activity against secondary mutations among patients with MET exon 14 skipping NSCLC, according to study findings.
After failure of type 1b MET tyrosine kinase inhibitors, foretinib shows potent activity against secondary mutations among patients with MET exon 14 skipping NSCLC, according to study findings.
After failure of type 1b MET...
06/20/2022
Oncology
News
09/22/2022
Findings from a recent study suggest that while Medicare eligibility and enrollment at age 65 led to increased utilization of some high-value and low-value care services, there were no changes in the utilization of most other services offered.
Findings from a recent study suggest that while Medicare eligibility and enrollment at age 65 led to increased utilization of some high-value and low-value care services, there were no changes in the utilization of most other services offered.
Findings from a recent study...
09/22/2022
Journal of Clinical Pathways
News
06/20/2022
Bevacizumab added to erlotinib improved PFS among Italian patients with EGFR-mutated NSCLC, according to results from the phase 3 BEVERLY trial.
Bevacizumab added to erlotinib improved PFS among Italian patients with EGFR-mutated NSCLC, according to results from the phase 3 BEVERLY trial.
Bevacizumab added to erlotinib...
06/20/2022
Oncology
Commentary
01/11/2024
At the start of every new year, millions of individuals make resolutions to improve their health, with many individuals aiming to lose weight, eat healthier, and exercise regularly. Unfortunately, many of these goals are often short-lived for...
At the start of every new year, millions of individuals make resolutions to improve their health, with many individuals aiming to lose weight, eat healthier, and exercise regularly. Unfortunately, many of these goals are often short-lived for...
At the start of every new year,...
01/11/2024
Pharmacy Learning Network